Electrophysiology and pharmacology of cardiac arrhythmias. VIII. Cardiac effects of diphenylhydantoin. A

Merritt, 1938, Sodium diphenylhydantoin in treatment of convulsive disorders, J.A.M.A., 111, 1068, 10.1001/jama.1938.02790380010004 Harris, 1950, Effects of diphenylhydantoin sodium (Dilantin sodium) and phenobarbital sodium upon ectopic ventricular tachycardia in acute myocardial infarction, Am. J. Physiol., 163, 505, 10.1152/ajplegacy.1950.163.3.505 Mosey, 1964, The effects of diphenylhydantoin sodium (Dilantin), procaine hydrochloride, procaine amide, hydrochloride and quinidine hydrochloride upon ouabain-induced ventricular tachycardia in unanesthetized dogs, Circulation, 10, 65, 10.1161/01.CIR.10.1.65 Coveno, 1955, Effectiveness of several antifibrillatory drugs in the hypothermic dog, Am. J. Physiol., 181, 54, 10.1152/ajplegacy.1955.181.1.54 Scherf, 1960, The effect of diphenylhydantoin (Dilantin) sodium on atrial flutter and fibrillation provoked by focal application of aconitine and delphinine, Am. Heart J., 60, 936, 10.1016/0002-8703(60)90125-3 Helfant, 1967, The electrophysiological properties of diphenylhydantoin sodium as compared to procaine amide in the normal and digitalis-intoxicated heart, Circulation, 36, 108, 10.1161/01.CIR.36.1.108 Leonard, 1958, The use of diphenylhydantoin (Dilantin) sodium in the treatment of ventricular tachycardia, Arch. Intern. Med., 101, 714, 10.1001/archinte.1958.00260160036005 Bigger, 1968, Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects, Circulation, 38, 363, 10.1161/01.CIR.38.2.363 Mercer, 1967, The current status of diphenylhydantoin in heart disease, Ann. Intern. Med., 67, 1084, 10.7326/0003-4819-67-5-1084 Rosen, 1967, Diphenylhydantoin in cardiac arrhythmias, Am. J. Cardiol., 20, 674, 10.1016/0002-9149(67)90011-2 Helfant, 1969, The clinical use of diphenylhydantoin (Dilantin) in the treatment and prevention of cardiac arrhythmias, Am. Heart J., 77, 315, 10.1016/0002-8703(69)90187-2 Bigger, 1972, Digitalis toxicity: Drug interactions promoting toxicity and the management of toxicity, Semin. Drug Treat., 2, 147 Eddy, 1969, Treatment of cardiac arrhythmias with phenytoin, Br. Heart J., 4, 270 Stone, 1971, Diphenylhydantoin in the prevention of recurring ventricular tachycardia, Circulation, 43, 420, 10.1161/01.CIR.43.3.420 Gianelly, 1967, Effects of lidocaine on ventricular arrhythmias in patients with coronary heart disease, N. Engl. J. Med., 277, 1215, 10.1056/NEJM196712072772301 Lovell, 1971, Phenytoin after recovery from myocardial infarction, Lancet, 2, 1055 Wit, 1975, Electrophysiological bases for cardiac arrhythmias after myocardial infarction; effects of coronary artery occlusion on transmembrane action potentials of ventricular muscle and Purkinje fibers, Arch. Intern. Med., 135, 459, 10.1001/archinte.1975.00330030109011 Karliner, 1967, Intravenous diphenylhydantoin sodium (Dilantin) in cardiac arrhythmias, Dis. Chest, 51, 256, 10.1378/chest.51.3.256 Conn, 1967, Newer drugs in the treatment of cardiac arrhythmia, Med. Clin. North Am., 51, 1223, 10.1016/S0025-7125(16)32990-X Lang, 1965, Digitalis toxicity: Treatment with diphenylhydantoin, Arch. Intern. Med., 116, 573, 10.1001/archinte.1965.03870040087018 Seuffert, 1968, Use of diphenylhydantoin in prevention and treatment of cardiac arrhythmias during general anesthesis, Anesth. Analg., 47, 322, 10.1213/00000539-196807000-00005 Harris, 1966, Use of diphenylhydantoin in the treatment of arrhythmias following open heart surgery, Surg. Forum, 17, 185 Gautam, 1969, Phenytoin in post-operative cardiac arrhythmias, Br. Heart J., 31, 641, 10.1136/hrt.31.5.641 Dill, 1956, Studies on 5, 5′-diphenylhydantoin (Dilantin) in animals and man, J. Pharmacol. Exp. Ther., 118, 363 Kutt, 1971, Biochemical and genetic factors regulating Dilantin metabolism in man, Ann. N. Y. Acad. Sci., 179, 704, 10.1111/j.1749-6632.1971.tb46946.x Wilensky, 1973, Inadequate serum levels after intramuscular administration of diphenylhydantoin, Neurology, 23, 318, 10.1212/WNL.23.3.318 Svensmark, 1964, 5, 5-diphenylhydantoin metabolism, blood levels and toxicity, Arch. Neurol. (Chicago), 11, 642, 10.1001/archneur.1964.00460240074010 Nayler, 1968, Some effects of diphenylhydantoin and propranolol on the cardiovascular system, Am. Heart J., 75, 83, 10.1016/0002-8703(68)90119-1 Noach, 1958, Studies on the absorption, distribution, fate and excretion of 4-C14-labeled diphenylhydantoin, J. Pharmacol. Exp. Ther., 122, 301 Butler, 1957, Metabolic conversion of 5-5-diphenylhydantoin to 5′-(p hydroxyphenyl)-5 phenylhydantoin, J. Pharmacol. Exp. Ther., 119, 1 Maynert, 1960, The metabolic fate of diphenylhydantoin in the dog, rat and man, J. Pharmacol. Exp. Ther., 130, 275 Kutt, 1966, Some causes of ineffectiveness of diphenylhydantoin, Arch. Neurol. (Chicago), 14, 489, 10.1001/archneur.1966.00470110033004 Kutt, 1970, Metabolism of diphenylhydantoin by rat liver microsomes I. Characteristics of the reaction, Biochem. Pharmacol., 19, 675, 10.1016/0006-2952(70)90230-3 Gerber, 1971, Study of dose-dependent metabolism of 5,5-dipheyylhydantoin in the rat using new methodology for isolation and quantitation of metabolites in vivo and in vitro, J. Pharmacol. Exp. Ther., 178, 567 Gerber, 1972, Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation, Res. Commun. Chem. Pathol. Pharmacol., 3, 455 Bigger, 1969, A method for the estimation of plasma diphenylhydantoin concentration, Am. Heart J., 77, 572, 10.1016/0002-8703(69)90169-0 Arnold, 1970, The rate of decline of diphenylhydantoin in human plasma, Clin. Pharmacol. Ther., 11, 121, 10.1002/cpt1970111121 Atkinson, 1973, Pharmakokinetic study of a patient with diphenylhydantoin toxicity, Clin. Pharmacol. Ther., 14, 521, 10.1002/cpt1973144part1521 Kutt, 1964, Diphenylhydantoin and phenobarbital toxicity; the role of liver disease, Arch. Neurol. (Chicago), 11, 649, 10.1001/archneur.1964.00460240081011 Karlin, 1970, Acute diphenylhydantoin intoxication following halothane anesthesia, J. Pediatr., 76, 941, 10.1016/S0022-3476(70)80383-3 Kutt, 1964, Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity, Neurology, 14, 542, 10.1212/WNL.14.6.542 Kutt, 1966, Some causes of ineffectiveness of diphenylhydantoin, Arch. Neurol. (Chicago), 14, 489, 10.1001/archneur.1966.00470110033004 Kutt, 1969, The effect of phenobarbital on plasma diphenylhydantoin level and metabolism in man and in rat liver microsomes, Neurology, 19, 611, 10.1212/WNL.19.6.611 Cucinell, 1965, Drug interactions in man. I. Lowering effect of phenobarbital on plasma levels of bishydroxycoumarin (Dicoumarol) and diphenylhydantoin (Dilantin), Clin. Pharmacol. Ther., 6, 420, 10.1002/cpt196564420 Kristensen, 1969, The influence of phenobarbital on the half-life of diphenylhydantoin in man, Acta Med. Scand., 185, 347, 10.1111/j.0954-6820.1969.tb07346.x Kutt, 1969, The effect of phenobarbital on plasma diphenylhydantoin level and metabolism in man and in rat liver microsomes, Neurology, 19, 611, 10.1212/WNL.19.6.611 Odar-Cederlöf, 1974, Kinetics of diphenylhydantoin in uraemic patients: Consequences of decreased plasma protein binding, Eur. J. Clin. Pharmacol., 7, 31, 10.1007/BF00614387 Reidenberg, 1971, Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function, N. Engl. J. Med., 285, 264, 10.1056/NEJM197107292850506